Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2025-07-31 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Appointment
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated 31st July 2025 from Sanofi India Limited addressed to stock exchanges, reporting the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended 30th June 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director and Site Director. The document contains extensive financial data including unaudited quarterly and half-year financial results, statements of assets and liabilities, and cash flows. The presence of unaudited financial statements with substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half-year) indicates this is an Interim / Quarterly Report. The management changes are included but are secondary to the main content of financial results. Therefore, the document fits best under the Interim / Quarterly Report (IR) category rather than a Board/Management Information (MANG) or Regulatory Filing (RNS). The document length (15,000 characters) and detailed financial tables confirm it is a full report, not just an announcement or certification. H1 2025
2025-07-31 English
Appointment
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated 31st July 2025 from Sanofi India Limited addressed to stock exchanges, reporting the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended 30th June 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director and Site Director. The document contains extensive financial data including income statements, balance sheets, and cash flow statements for the half-year period, which are unaudited but reviewed. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarter and half-year) indicates this is an Interim / Quarterly Report. The management changes are included but are secondary to the main content of financial results. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-07-31 English
We have enclosed a copy of Financial Results for the Quarter and Half-year ended 30th June 2025.
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement dated 31st July 2025 from Sanofi India Limited regarding the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended 30th June 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director and Site Director. The financial data includes comprehensive unaudited financial results, statement of assets and liabilities, and cash flow statements for the half-year period. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half-year) confirms this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains the actual financial statements and management information. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-07-31 English
Retirement
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated 31st July 2025 from Sanofi India Limited addressed to stock exchanges, reporting the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended 30th June 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director and Site Director. The document contains extensive financial data including unaudited financial results, statement of assets and liabilities, and cash flows for the half year ended June 30, 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarter and half-year) indicates this is an Interim / Quarterly Report. The management changes are included but are secondary to the main content of financial results. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-07-31 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Sanofi India Limited dated 31st July 2025, reporting the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended 30th June 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director. The financial data includes comprehensive unaudited financial results, statement of assets and liabilities, and cash flow statements for the half-year period. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half-year) indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains the actual financial statements and detailed management information. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-07-31 English
Outcome of the Board Meeting held on 31st July 2025 is enclosed.
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated July 31, 2025, from Sanofi India Limited addressed to stock exchanges, reporting the outcome of a Board Meeting. It includes approval of unaudited financial statements for the quarter and half-year ended June 30, 2025, along with a Limited Review Report. The document also announces management changes: retirement of a Whole-time Director and appointment of a new Whole-time Director and Site Director. The document contains extensive financial data including unaudited financial results, statement of assets and liabilities, and cash flow statements for the half-year period. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarter and half-year) indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report but contains substantive financial data and management information. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-07-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.